An update on biology, diagnosis and treatment of primary plasma cell leukemia.

abstract：:β-thalassemias are caused by nearly 300 mutations of the β-globin gene, leading to a low or absent production of adult hemoglobin (HbA). Two major therapeutic approaches have recently been proposed: gene therapy and induction of fetal hemoglobin (HbF) with the objective of achieving clinically relevant levels of Hbs. ...

journal_title：Expert review of hematology

authors： Breda L,Rivella S,Zuccato C,Gambari R

更新日期：2013-06-01 00:00:00

abstract：:Thromboembolic diseases require anticoagulation for their prevention and treatment. New oral anticoagulants, specifically direct factor Xa and thrombin inhibitors, were developed to overcome the limitations of conventional anticoagulants. Their benefit has been demonstrated using fixed doses without laboratory-guided ...

journal_title：Expert review of hematology

authors： Harenberg J,Marx S,Erdle S,Krämer R

更新日期：2012-02-01 00:00:00

abstract：:Ofatumumab is a humanized second-generation monoclonal antibody with the affinity to a transmembrane protein CD20. In in vitro studies, it exhibits higher efficacy towards chronic lymphocytic leukemia (CLL) cells compared to rituximab, and it can be explained by the fact that its epitope on the target CD20 protein is ...

journal_title：Expert review of hematology

authors： Grosicki S

更新日期：2015-06-01 00:00:00

abstract：:Professor John Gribben is Chair of the International Workshop on non-Hodgkin Lymphoma and the Gordon Hamilton Fairley Chair of Medical Oncology at St. Bartholomew's Hospital, Bart's Cancer Institute, London, UK, a Cancer Research UK Centre of Excellence. His doctoral studies were performed at University College London...

journal_title：Expert review of hematology

authors： Gribben J

更新日期：2013-04-01 00:00:00

abstract：:Anti-CD20 monoclonal antibodies (mAbs), rituximab, ofatumumab and obinutuzumab, have a significant impact in the treatment of chronic lymphocytic leukemia (CLL), particularly in combination with chemotherapy. Over the last few years, several new mAbs have been developed and investigated in CLL. The most promising newe...

journal_title：Expert review of hematology

authors： Robak T

更新日期：2014-12-01 00:00:00

abstract：INTRODUCTION:Catastrophic antiphospholipid syndrome (CAPS) is a rare, life-threatening disease. In 1992, Asherson defined it as a widespread coagulopathy related to the antiphospholipid antibodies (aPL). CAPS requires rapid diagnosis and prompt initiation of treatment. Areas covered: This paper discusses all aspects of...

journal_title：Expert review of hematology

authors： Carmi O,Berla M,Shoenfeld Y,Levy Y

更新日期：2017-04-01 00:00:00

abstract：:Recombinant IFN-α (rIFN-α) induces complete hematologic remissions in patients with myeloproliferative neoplasms (MPNs), but its use has been limited by side effects owing to the relatively high doses used. Now, low-dose rIFN-α is stressed, starting relatively early in the course of the MPNs. In polycythemia vera, thi...

journal_title：Expert review of hematology

authors： Silver RT,Kiladjian JJ,Hasselbalch HC

更新日期：2013-02-01 00:00:00

abstract：:Despite significant improvements in treatment modalities over the 10 years, the clinical course of patients with follicular lymphoma (FL) remains heterogeneous. Thus, prognostic indexes are still required to direct treatment choices and for the design of clinical trials. Investigators have conducted a variety of studi...

journal_title：Expert review of hematology

authors： Luminari S,Cox MC,Montanini A,Federico M

更新日期：2009-10-01 00:00:00

abstract：INTRODUCTION:In the last decade, the availability of new drugs for the treatment of Multiple Myeloma (MM) significantly improved patients' outcomes, but also raised attention towards a new spectrum of adverse events. Recently, four novel agents with different mechanisms of action (carfilzomib, elotuzumab, daratumumab a...

journal_title：Expert review of hematology

authors： Brioli A,Mügge LO,Hochhaus A,Von Lilienfeld-Toal M

更新日期：2017-03-01 00:00:00

abstract：:Akt is a Ser-Thr kinase with pleiotropic effects on cell survival, growth and metabolism. Recent evidence from gene-deletion studies in mice, and analysis of human platelets treated with Akt inhibitors, suggest that Akt regulates platelet activation, with potential consequences for thrombosis. Akt activation is regula...

journal_title：Expert review of hematology

authors： Woulfe DS

更新日期：2010-02-01 00:00:00

abstract：:Asparaginase has been a mainstay of therapy in the treatment of acute lymphoblastic leukemia since the 1970s. There are two major preparations available and FDA approved in the United States today, one derived from Escherichia coli and the other from Erwinia chrysanthemi. Erwinia asparaginase is antigenically distinct...

journal_title：Expert review of hematology

authors： Figueiredo L,Cole PD,Drachtman RA

更新日期：2016-03-01 00:00:00

abstract：:Hemopoietic stem-cell transplant patients may require intensive blood component support. Complications of transfusions include transmission of viral and bacterial infections, transfusion-associated graft-versus-host disease and transfusion-related acute lung injury. Alloimmunization to red cell antigens may cause diff...

journal_title：Expert review of hematology

authors： Radia R,Pamphilon D

更新日期：2011-04-01 00:00:00

abstract：:Hematopoietic stem cells can be mobilized out of the bone marrow into the blood for the reconstitution of hematopoiesis following high-dose therapy. Methods to improve mobilization efficiency and yields are rapidly emerging. Traditional methods include chemotherapy with or without myeloid growth factors. Plerixafor, a...

journal_title：Expert review of hematology

authors： Damon LE,Damon LE

更新日期：2009-12-01 00:00:00

abstract：INTRODUCTION:Haploidentical stem cell transplantation (Haplo-SCT) is currently a suitable alternative worldwide for patients with hematological diseases, who lack human leukocyte antigen (HLA)-matched siblings or unrelated donors. Areas covered: This review summarizes the advancements in Haplo-SCT in recent years, prim...

journal_title：Expert review of hematology

authors： Sun YQ,Chang YJ,Huang XJ

更新日期：2018-04-01 00:00:00

abstract：INTRODUCTION:Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are considered indolent lymphocytic malignancies, more often requiring active surveillance rather than intervention. Despite the indolent nature of CLL/SLL, treatment is likely indicated in a patients' lifetime. Recent changes in the t...

journal_title：Expert review of hematology

authors： Tees MT,Flinn IW

更新日期：2017-02-01 00:00:00

abstract：:Many patients with acute myeloid leukemia will eventually develop refractory or relapsed disease. In the absence of standard therapy for this population, there is currently an urgent unmet need for novel therapeutic agents. Targeted therapy with small molecule inhibitors represents a new therapeutic intervention that ...

journal_title：Expert review of hematology

authors： Al-Hussaini M,DiPersio JF

更新日期：2014-08-01 00:00:00

abstract：:Introduction: There is emerging evidence linking the commensal gut microbiota with the development of cardiovascular disease and arterial thrombosis. In immunothrombosis, the host clotting system protects against the dissemination of invading microbes, not considering the huge number of microbes that interact with hos...

journal_title：Expert review of hematology

authors： Formes H,Reinhardt C

更新日期：2019-07-01 00:00:00

abstract：:Over two-thirds of newly diagnosed multiple myeloma are over 65 years. The treatment goals for the non-transplant-eligible patients should be to prolong survival by achieving the best response, while ensuring quality of life. New upfront treatment combinations based on first generation of novel proteasome inhibitors a...

journal_title：Expert review of hematology

authors： Mateos MV,Leleu X,Palumbo A,San Miguel JF

更新日期：2014-02-01 00:00:00

abstract：:Key paper evaluation: Craddock C, et al. Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia. J Clin Oncol. 2019; 37: 580-8. Allogeneic hematopoietic stem cell transplant (allo-HSCT) is the only potentially cura...

journal_title：Expert review of hematology

authors： Bewersdorf JP,Stahl M,Zeidan AM

更新日期：2019-08-01 00:00:00

abstract：:Although guidelines exist to deal with some aspects of platelet transfusion practice, many important clinical issues have not been addressed in large randomized controlled trials (RCTs). Slichter et al. conducted a RCT of prophylactic platelet transfusions to determine the effects of the dose of platelets on clinical ...

journal_title：Expert review of hematology

authors： Cid J,Lozano M

更新日期：2010-08-01 00:00:00

abstract：INTRODUCTION:Acute lymphoblastic leukemia (ALL) is an aggressive type of leukemia that carries poor prognosis in adults especially in the setting of high risk cytogenetics and relapsed/refractory (R/R) disease. Advancements in immunotherapy have led to the development of several monoclonal antibodies (MoAbs) and chimer...

journal_title：Expert review of hematology

authors： Valecha GK,Ibrahim U,Ghanem S,Asti D,Atallah JP,Terjanian T

更新日期：2017-09-01 00:00:00

abstract：INTRODUCTION:While associated life-threatening and fatal bleeding events are less frequent with the direct factor Xa inhibitors compared to vitamin K antagonists, significant concern surrounding management of major bleeds and urgent periprocedural interruption of these agents exists among clinicians. Andexanet alfa is ...

journal_title：Expert review of hematology

authors： Cervi A,Crowther M

更新日期：2018-11-01 00:00:00

abstract：:Recent studies have identified recurrent mutations in genes that encode proteins crucial in the epigenetic regulation of gene transcription in hematologic malignancies. Somatic mutations in epigenetic modifiers, including IDH1, IDH2, TET2, DNAMT3A, ASXL1, MLL and EZH2 are enriched in patients with acute myeloid leukem...

journal_title：Expert review of hematology

authors： Hou HA,Tien HF

更新日期：2016-05-01 00:00:00

abstract：INTRODUCTION:Multiple myeloma (MM) is characterized by notable inter-patient and intra-clonal heterogeneity that is gradually decoded over the last decade. Despite the deeper and better understanding of its biology and the development of novel therapeutic strategies that have prolonged overall survival, MM still retain...

journal_title：Expert review of hematology

authors： Ziogas DC,Dimopoulos MA,Kastritis E

更新日期：2018-11-01 00:00:00

abstract：:Adult T-cell leukemia-lymphoma (ATL) is a peripheral T-cell malignancy, closely associated with human T-cell lymphotropic virus type I infection. Clinically, ATL is classified into four subtypes: acute, lymphoma, chronic and smoldering type. Although the prognosis of chronic and smoldering-type ATL is relatively good,...

journal_title：Expert review of hematology

authors： Tanosaki R,Tobinai K

更新日期：2010-12-01 00:00:00

abstract：:The fms-like tyrosine kinase 3 (FLT3) plays an important role in both normal and malignant hematopoiesis. Activating mutations in the FLT3 receptor can be detected in approximately 30% of acute myeloid leukemias (AMLs) and are associated with a distinctly poor clinical outcome for patients. There are now several class...

journal_title：Expert review of hematology

authors： el-Shami K,Stone RM,Smith BD

更新日期：2008-12-01 00:00:00

abstract：INTRODUCTION:Peripheral T cell lymphomas (PTCL) are a heterogenous group of lymphoproliferative disorders which are generally not curable with conventional chemotherapy and associated with inferior outcomes. Pralatrexate is a novel folate analog, the first FDA approved drug) for the treatment of relapsed/refractory (R/...

journal_title：Expert review of hematology

authors： Jennifer C Z,Sara Mohamed J,Salma A,Francine F

更新日期：2020-06-01 00:00:00

abstract：:Introduction: The genomic landscape of Waldenström macroglobulinemia (WM) is characterized by recurrent MYD88 (MYD88L265P) and CXCR4 mutations (CXCR4MUT), detected in 90% and 30% of cases, respectively. The role of CXCR4MUT in clinical features and outcomes to therapy in WM patients is evolving. Areas covered: We perf...

journal_title：Expert review of hematology

authors： Castillo JJ,Moreno DF,Arbelaez MI,Hunter ZR,Treon SP

更新日期：2019-10-01 00:00:00

abstract：INTRODUCTION:Inhibitors against factor VIII (FVIII), which develop in around 20-30% of patients with severe hemophilia A, represent a significant complication of on-demand or prophylactic FVIII therapy. Currently, the main treatment option for inhibitor patients is eradication using immune tolerance induction (ITI) the...

journal_title：Expert review of hematology

authors： Oldenburg J,Young G,Santagostino E,Escuriola Ettingshausen C

更新日期：2018-11-01 00:00:00

abstract：:Venous thromboembolism is a common cause of morbidity and mortality among patients undergoing elective orthopedic surgery. Due to the high incidence of venous thromboembolism in this setting, perioperative anticoagulation is the recommended approach for thromboprophylaxis. Low molecular weight heparin (LMWH), fondapar...

journal_title：Expert review of hematology

authors： Rachidi S,Aldin ES,Greenberg C,Sachs B,Streiff M,Zeidan AM

更新日期：2013-12-01 00:00:00